Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1.

Faunce T, Townsend R, McEwan A.

J Law Med. 2010 Sep;18(1):38-49.

PMID:
20977160
3.

A message from the Vioxx case.

Baldwin HJ, Droege M, Daniel KL.

Am J Health Syst Pharm. 2006 Mar 15;63(6):503. No abstract available.

PMID:
16522877
4.

What have we learnt from Vioxx?

Krumholz HM, Ross JS, Presler AH, Egilman DS.

BMJ. 2007 Jan 20;334(7585):120-3. Review. No abstract available.

6.

US judge dismisses 50m dollars damages in Vioxx lawsuit.

Charatan F.

BMJ. 2006 Sep 9;333(7567):516. No abstract available.

7.

The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.

Cahana A, Mauron A.

J Anesth. 2006;20(4):348-51. No abstract available.

PMID:
17072707
8.

Vioxx doctors wooed by Merck are now its foes.

Tesoriero HW.

Wall St J (East Ed). 2006 Mar 10:B1, B3. No abstract available.

PMID:
16578911
9.

Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.

Moynihan R.

BMJ. 2009 Apr 6;338:b1432. doi: 10.1136/bmj.b1432. No abstract available.

PMID:
19349350
10.

Quebec allows Vioxx class-action suit.

Sibbald B.

CMAJ. 2007 Jan 2;176(1):20. No abstract available.

11.

The preacher who's raising hell with Merck.

Parloff R.

Fortune. 2005 Aug 8;152(3):20. No abstract available.

PMID:
16097189
12.

Merck disguised "marketing publication" as medical journal to help promote Vioxx, court hears.

Moynihan R.

BMJ. 2009 Apr 28;338:b1714. doi: 10.1136/bmj.b1714. No abstract available.

PMID:
19401326
13.

Bringing the FDA's Information to Market.

Woloshin S, Schwartz LM.

Arch Intern Med. 2009 Nov 23;169(21):1985-7. doi: 10.1001/archinternmed.2009.399. No abstract available.

PMID:
19933960
15.

Open conflict on the handling of the Merck drug Vioxx by editorial giants.

Edwards RG.

Reprod Biomed Online. 2006 Dec;13(6):905. No abstract available.

PMID:
17169217
16.

Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".

Luepker RV.

Arch Intern Med. 2010 Jan 25;170(2):202. doi: 10.1001/archinternmed.2009.496. No abstract available.

PMID:
20101016
18.

Merck defends Vioxx in court, as publisher apologises for fake journal.

Moynihan R.

BMJ. 2009 May 11;338:b1914. doi: 10.1136/bmj.b1914. No abstract available.

PMID:
19433504
19.

94% of patients suing Merck over rofecoxib agree to company's offer.

Charatan F.

BMJ. 2008 Mar 15;336(7644):580-1. doi: 10.1136/bmj.39513.541296.DB. No abstract available.

20.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155

Supplemental Content

Support Center